Hear expert guidance on how to inform decisions about advancing therapy and to recognize all patients who would benefit from approved biologic therapies targeting IL-13 based on the pathophysiology of Atopic Dermatitis.
Join us for a complimentary dinner and CME as our experts discuss the latest efficacy and safety data from clinical trials of newly approved and emerging therapies and new therapeutic combinations for small cell lung cancer (SCLC).